Eli Lilly & Co.: PharmaVitae Profile

This analysis examines the historical and forecast performance for Eli Lilly in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

GlaxoSmithKline plc: PharmaVitae Profile

This analysis examines the historical and forecast performance for GSK in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Multiple Sclerosis - Tysabri to prevail despite safety setbacks

Spurred by uptake of Biogen Idec and Elan's Tysabri (natalizumab) and continued revenue growth for the three beta-interferon brands and Teva's Copaxone (glatiramer acetate), the seven major multiple sclerosis market value increased 15.1% from 2006 to $5.3 billion in 2007.

Top 20 Therapy Cancer Brands - Key brands set to consolidate advantage as competition

Cancer therapy brand sales totaled over $30 billion in the seven major markets in 2007, growing by 20.1% since 2006. The high growth of this market makes it attractive to companies keen to emulate the blockbuster status achieved by several brands. However, with several impending patent expiries due, companies will need to work hard to maximize their return throughout the lifecycle of their brands.

Antihormonal Therapy Cancer Brands - Careful lifecycle management needed to preserve brand

Antihormonal therapies are a class of cancer therapeutics that generated branded drug sales of $5.8 billion in the seven major pharmaceutical markets in 2007. However, the relative maturity of the market means that it is has become a highly genericized therapeutic class. Even still, the lack of innovation within this saturated market helps many leading brands retain their success.

Insomnia - Orexin and serotonin receptor modulators to innovate market

After 3 years of steady growth, the value of the insomnia market across the seven major markets (7MM) slumped by 12% to $4.1 billion in 2007 due to rapid generic erosion of Sanofi-Aventis's market leader Ambien (zolpidem) in the US. However, this downturn will be short-lived and the market will regain growth from 2009 to $6.9 billion in 2017 driven by the launch of new treatments across the 7MM.

Commercial Insight: HIV - The battle for market share is getting fiercer

In 2007, HIV drugs achieved sales of $9.3 billion in the 7MM, growing faster than the overall market at a CAGR of 11.3% from 2004-2007. Due to patent expirations, Datamonitor expects the market's growth to slow down somewhat, reaching total sales of $15.1 billion in 2017. Among the ROW, the Canadian HIV market in 2007 was worth $272 million, achieving a CAGR of 24% from 2004-2007.

Big Pharma M&A Analysis to 2012 - Surveying the growth rate landscape

With sales growth rates expected to fall below their historic levels, Big Pharma must act to bolster its performance out to 2012 if it is to maintain the investment community's valuation of its stocks. One mechanism for plugging the sales growth rate gap and fulfilling investors' 'growth imperative' is M&A activity.

An Analysis of Access to Finance for European Biotechnology Firms

The financial contest is probably the biggest barrier to European competitiveness in biotechnology. Very young start-up companies frequently struggle to raise cash to start the business. It is becoming more difficult than before. However, there are an increasing number of national and regional schemes that provide money to young companies.

Full 43 pages report is available for free at our Downloads section. 

'Conservative' pharmaceutical industry slow to take advantage of online marketing opportunities

While the internet has altered the landscape in the retail sector and revolutionized the airline industry, pharmaceutical companies have been slow to take advantage of the marketing opportunities offered by the medium. With existing sales and marketing strategies widely considered unsustainable, the industry needs to evolve and engage with its customers online, or it risks being left behind. 

Drug Repositioning Strategies - Serendipity by design

Drug repositioning has several advantages over traditional discovery-reduced cost, risk and time to market-compared with traditional discovery, providing an attractive prospect for Big Pharma, scrambling to fill pipelines in an increasingly harsh market environment. As competition to inlicense candidates drives the price of this strategy up, repositioning presents a cost effective alternative.

Osteoarthritis - The COX-2 pipeline collapses

With several recent non-approvable decisions in the osteoarthritis market since 2006, Datamonitor has updated its forecast to account for the effect on the market. We have revised the market outlook over the next 10 years using the latest IMS data. We expect the market to grow steadily, with a CAGR from 2007 to 2017 of 3.2%, to reach sales of nearly $5.5 billion in 2017.

Acute Stroke: Commercial risk offsets high unmet need

Stroke is one of the top three causes of death and its incidence in the seven major markets is expected to increase in the next ten years because of an aging population. Long term disability caused by stroke is a major economic burden on healthcare systems, current treatment options are limited and general awareness of stroke is poor.

Online Patient Recruitment Strategies - Optimizing the clinical trial process

With the rising costs, length and complexity of clinical trials, drug development is subject to huge delays, translating into delays in getting a drug to market and millions of dollars in lost sales. Optimizing the recruitment process through web-based technologies can cut delays in clinical trials and can also be used to maintain relationships with patients to improve the clinical trial process.

Non-insulin antidiabetics – Incretin mimetics – leaders in a diverse pipeline

Datamonitor expects incretin mimetics to emerge as a major new therapeutic class in non-insulin antidiabetics, driven by an explosion in the patient population, safety fears surrounding established therapies and significant unmet patient needs.

Pricing & Reimbursement - Seven Major Markets Update

Governments and payers across the seven major markets are implementing cost-cutting initiatives to combat escalating healthcare costs, putting even greater pressure on pharma companies. In addition to the credit crunch, ever fewer novel products are coming to market, contributing to the declining return on investment.

Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets

Innovative Clinical Trial Design and Management is a report published by Business Insights that explores the major types of adaptive design and their role in dose-finding. The report investigates seamless Phase 2/3 trials and adaptive trials in pharmacogenomics, assesses the logistical implications of adaptive trial implementations and reviews the current regulatory standpoints of the FDA and EMEA.

The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends

Emerging Role of Postmarketing Clinical Research is a report published by Business Insights that uses detailed case studies and market scenarios to examine the latest issues surrounding phase IV trial applications. The potential to leverage competitive advantage with postmarketing research is assessed by measuring the implications for formulary access, product marketing, indication expansion and reimbursement coverage.